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ejection fincilm and a” increase in pima tm-ewphria (ti = 
-0.1.9, p c 0.wlO1), plum0 rain actlvlly mill = -0.24, p < 
0.0001) and a&dne vpwpre& (rho = -0.12, p < 0.003). The 
only mKqtlcm wtw llrlal natrlttnllc peptkk, rkkh skewed Ike 
Plasma norepinephrine (1.2). plasma atria1 natriuretic pep- classes II and 111 with left ventricular ejection fraction 
tide (3) and plasma renin activity are increased in patients 535%) with symptoms of hean failure requiring treatment 
with heart failure (4). Despite progress in understanding the (IO). The reciatry was conducted in I8 of the 23 SOLVD 
pathophysiology of heart failure, the mechanisms underlying centers. Patients with ejection fraction 10.45% or a radio- 
the activation of the neurohumoral systems m patients with logically confirmed discharge diagnosis of congestive heart 
long-sianding congestive heart failure are not well under- Failure during the period January I, 1988 to February 28, 
stood. In particular, it is not clear whether severity of 1989 were invited to participate. Patients with nonvalvular 
impairment in left ventricular function or degree of ,ymp congeniral heart disease. any noncardiac life-threatening 
tans relate to the level of neurohumoral activation. When disease. lack of reliable means of follow-up or failure to 
cardiac output decreases after myocardial damage. neurv consent were excluded. Baseline information abstracted 
hormones are activated to preserve circulatory homcostasis. from the patients‘ charts included the following: demo- 
Thus, the severity of myocardial damage. impairment of left gnphic data. clinical history, physical examination. ejection 
ventricular function and severity of symptoms may relate to fraction. etiology of the disease, chest X-ray film. medica- 
the degree of neurohumoral activation. For example. an tion used. electrocardiogram (ECG) and laboratory results. 
increase in arginine vasopressin levels in patients with From the 6.273 patients recruited into the SOLVD Reg- 
congestive heart failure has been found to correlate directly ~str: a subgroup of 898 patierts were randomly selected on 
with hemodynamic severity of heart failure IS). Further. the basis of etiology to obtain more data on “rarer” etiolo- 
these neurohumoral responses may also be modified by gies (Jh”c of registry patients with ischemic or hypeilensive 
patient age and by etiology of the disease. In the saperimen- heart disease. IW% of patients with other etiologies). Details 
trd study by Watkins et al. (6). a reduction in cardiac output of regary methods and sampling procedures have been 
and decrease in blood pressure resulted in elevation of published clscwhcre (II). In this subgroup a detailed history 
plasma rain activity and associated vasoconstriction and WBE obtained. and physical examination. two-dimensional 
sodium retention. However. the circulating Inrurohumoral cchocnrdiography. ejection fraction. chest X-ray film. I?- 
mechanisms returned to normal during the compensated lead ECG and a 6.mitt wdk test (12) were conducted. Of 
state of heart Failure us plasma volume and cardiac stroke these pat,e”ts. 859 (%%I had at least one mra~“reme”t of 
volume increased. Previous clinical studies in patients with neuruhormone levels; the present analyses mere conducted 
stable heart failure have demonstrated only a modest corre- using this sample. In addition. neurohormonal levels were 
lation between impaired left ventricular functron and neuro- 
humoral activation (7.8). However. none of the studies took 
into account the interrelation of factors, such as age. sever- 
ity of symptoms or use of drngs. 
The Studies of Left Ventricular Dysfunction (SOLVD) 
Registry included patients with a wide range of depressed 
left ventricular function to explore the relation between 
neurohumoral activtttion and severity of left ventricular 
dysfunction in congestive heart failure. In a randomly se- 
lected group of patients from this SOLVD Registry. we 
tested the association of olasma neurohormone levels with 
obteinrd in 56 age- and gender-matched control subjects 
with no history or physical findings of heart disease or 
hypertension. None were taking medications known to in- 
fluence neurohormone levels. 
The study protocol was approved by the local hospitnl 
review hoards and the National Institutes of Health. All 
control subjects and patients provided written informed 
consent. 
Neurohormone measurements. An intmvenous cannula 
(short 18. or 20.gauge plastic catheter connected to a three- 
way stopcock) was inserted in an rwm vein. The catheter was 
left ventticular ejection f&ztion, New York Heart Associa- Rughedwith heparinized saline solution, and patients were 
tion functional class and other clinical variables after con- then allowed to rest supine in a quiet room for 30 min. Five 
trolling for selected covariates. In particular. we examined milliliters of blood was placed into a prechilled tube contain- 
tltose neumhorrnones that have been previously demon- ing reduced glutathione and ethylenebis (oayethylenenitrilo) 
strated to be increased in patients with cougesiive hean tetraacetic acid for measurement of plasma norepinephrine. 
failure (l-5). The sample was centrifuged within I h al 4°C at 2.5QO rpm for 
I2 min. Plasma was then stored at -20°C or colder. Five 
Methods 
Study da&n. The SOLVD was a multicenter program of 
research in patients with left ventricular dysfunction and 
heart failure. It included two trials and a registry. The 
Prevention Trial showed that enalapril. a converting enzyme 
inhibitor, prevented the development of symptoms of heart 
failure in patients with a left ventricular ejeclion fraction 
s3S% without therapy for heart failure (9). The Treatment 
Trial demonstrated that enalapril reduced morlality in pa- 
tients with mild to moderate heart failure (mainly functional 
milliliters each for plasma renin activity, arginine vasopres- 
sin and atrial natriuretic peptide analysis were placed into 
prechilled evacuated tubes containing sodium ethylenedi- 
ammetetracrtic acid. The three tubes were mixed gently 
and were placed on ice and centrifuged within I h of 
collection ut 4°C at 2,500 rpm for I2 min. The supernatant 
plasma was stored as for plasma norepinephrinr. 
Neurohormone assays. Samples were shipped on dry ice 
to the neurohormone core laboratory at the University of 
Texas Medical School at Houston. Plasma norepinephrine 
was measured by a radioenzymatic method (13). Plasma 
rcnin activity was measured using the moditicd radic- 
immunoassay technique of Serdey and Larz8h (14). Plasma 
arginine vasopressin and atrial natriuretic peptide were 
measured by a simplified radioimmunoassay using commcr- 
ciaIly available antibodies (15). All samples were analyzed in 
a blinded manner without knowledge of the patients’ char- 
acteristics. 
SensiIiviIy and reproducibility of assays. The rediwnzy- 
matic assay for plasma norcpincphrine has a sensitivity of 
1 pglml with a sample/blank radiiactivity count ratio >2. In 
addition, the interassay coefficient of variation was 6.1% 
(calculated from 20 different assays done conscculively on 
20 different days). The radioimmunoassay for plasma renin 
activity is dependent on the sensitivity of the antibody used 
in the assay. which can reliably detect 2 pg of an&!iotensin I 
(sampleiblank ratio 2). This assay can detect very low 
plasma rcnin activity 10. I ndml per h). The interessay 
coefficient of variation for plasma rain activity was 12.6%. 
The radioimmunoassay for atrial natriurctic peptide hes a 
sensitiviry of 2 pglml, and the sensitivity for arginine vase 
prcssin is 0.22 pgiml. The interassay coefficients of variation 
for alrial natriurctic peptide and argininc vasopressin were 
13.7% and 11.6%. respectively. In addilion, previously as- 
sayed quality control samples of plasma norcpinephrlne 
were mailed every 2 months from the core laboratory to the 
SOLVD study centers. These sampler were stored and 
returned in the same way as the patient samples. OR return 
these quality control sampler were reanalyzed IO assess the 
stability of samples during slorage and lranspottation. There 
were no significant differences in Ihe plasma norepinephrine 
values (278 + 28 vs. 269 ? 32 pglml, p = NS) in 123 samples 
analyzed in this manner. 
Left ventricular dimensions and ejection fraction were 
measured by two-dimensional echocardiography using the 
multiple diameter method (16). Left ventricular dimensions 
were measured below the tip of the mitral leaflets at end- 
diaslole (onset of QRS complex) and a1 end-sys~ole (one 
frame before mitral valve ooenina). The raerae vatiabilitv 
in ejection fraction rneasllrerne~t was <3S Left at&l 
dimensions were taken al the point of maximal anterior root 
motion in the sume plane as the sonic root. In most cases 
(78.4%) ejection fraction was measured on the fame day IhaI 
neurohomtone levels were determined. All left venIrictdar 
meesurcmcnts were made by the echocardiogmphic core 
laboratory at Baylor College of Medicine in Houston. 
StaIkIllI methudr. The “eurohormonal data wcrc not 
ttormallv distributed. Simple comuarisons and correlations 
were U&fore conducted using’ nonparameIric methods 
(e.g., Spea’man rho correlation [I’ll). The rest of the a&y. 
scs were multivariate linear models conducted on the natuml 
logarithms of the neurohonnone values (IS). This Iransfor- 
mation was selected because it wns found to make the 
distributions normal or near normal. All models were ad- 
justed for clinic (I7 dummy codes to define the I8 clinics) 
and ehology (one dummy EL- to dctemtine ischemic o: 
hypertensive heart disease vs. other etiolo& This latter 
adjustment was to control for the differing proportions of 
etiologies represented, by design, in the sample. Eighteen 
clinical variables were tested against each of the ncurohor- 
moncs.* Ejection fraction end all other continuous variables 
were treated as such in the models. Two dummy variables 
categorized hmclional class at three levels: class I versus II 
v&s III/IV. Concomitant drug use (angiotcnsin-converting 
enzyme or diuretic agents. or both) was also categorized at 
three levels: neither versus one versus both types of medi- 
cation prescribed. All other categoric variables were consid- 
ered at two levels. All p values arc two-tailed. 
Beeline clinkal da& A total of 6,273 pticnts were 
recruited into the rcgista on the basis of an ejection frac- 
tion 545% (87%) or radiologic evidence of congestive heart 
failure (13%). Of these, 69% had signs of congestive heert 
failure (defined as the presence of edema. third heart sound 
(S~)gallop. elevated jugular venous prcsaure on examination 
or history of breathlessness on exertion). In the registry. as 
in the main SOLVD bial, ischemic bearI disease was Ihe 
dominant cliology of heart failure. However, in Ihe subgroup 
of 859 patients participating in the present analysis, the 
frequency of ctiolony was ditTcrcnt because of stratlllcatiou 
that oversamplcd subjects with heart failure due to etiolonks 
other tbau ischemic or hypertensive heart disease. The 
chnracteristics of patients entering Ibe tunistry substudy are 
prexnted in Table I. Tbe age and gender disbibution was 
comparabk IO Ihal of ~hc conlml grow. The avctwe ant in 
Ihe registry snbsktdy grouu was 59 * 12 years (mean L SD. 
range 21 to 91); in Ibe cotnrol group Ibe average age was 
56 + I2 years (range 37 IO 80). Men comprised 7S% of Ibc 
pa&ipants in tbc rcgis~ry substudy. end underlying isch- 
emic heart disease wns prcscnt in 52%. In Ihe coatrol group 
70% were men. In the registry subsludy group the man 
cardiothoracic ratio and I& ventricular ejection fraction 
were 0.53 f 0.07 end 30.0 + 9.0%. respectively. Median 
values and interquartile rangeS (25% lo 75%) for all four 
neumhomtonas were signilicnn!ly higher in patients entering 
Ihe registry suUudy compared with control subjects lplas- 
ma norepimphrine, 420 I312 ID 5911 vs. 316 1246 to 4461 
pt$ml, p < O.llKU: plasma rcnin activily. 1.3 [0.4 lo 4.51 vs. 
0.5 10.3 IO 0.81 na/ml ccr h. D < O.MxII: atrial natriurclic 
p&de. 72 [4iIo-1301’~s. 48 i3l to 541 &nl. p c O.ooOl; 
arginine vasoprcsain. 2.2 11.7 to 2.91 YE. I.8 11.4 to 2.41 
pglml. p x O.ooO7. respectively). 
Neuruhormw lcvek and kll venkieulnr func~kn. Figure 
1 shows the &lion beIwccn ejecIioo fraftion and ncuro 
Table 1. Patient Characteristics log atrial natriureric peptide (p < O.ObOl) but not to log 
arginins vasoprersin (Table 2). 
WC also examined the relaticn between neurohormones 
and left at&J we and left ventricular systolic or diastolic 
dimensions All four neuoohortnones statistically signifi- 
cantly ctrrelatcd with either left altial size or left ventricular 
systolic or diastolic dimensions (Table 31. However, except 
for atnal natriuretic peptide, correlations with other neuro- 
hormones were weak. Plasma atrial natriuretic peptide level 
most closely correlated with leR atrial size Rho = 0.34, P i 
0.0001) and left ventricular systolic volume (rho = 0.30. p c 
0 OihJtJ. This is consistent rvith the observation that of the 
four neurohortnones examined. atrial natriurstic peptide 
showd the beqt comelation with cardiothoracic ratio on 
chest X-my film (rho = 0.30, p 4 O.ooOll. This associa:ion 
between enlarged cardiac size and atrial nattiuretic peptide 
levels is supported further by the fact that patients with 
elevated jugular venous pressure had significantly higher 
levels of otrial natriuretic oentide. as did those with uulmo- 
nary edema (p c O.OOOI fir both analysee3. 
hormones. There was a weak bnt significant correltttiun 
between dwesse in ejection fraction and increase in plasma 
noreoineohrine (rho = -0.18. D < O.onOt:. nlnsma renin 
act& (rho = -0.24. p < O.CMOI) and arginine vnsopressin 
(rho = -0.12, p < 0.003). The only exception was avial 
natriurelic peptide. which showed the best correlation with 
ejection fraction (rho = -0.37. p < 0.0001). Because pa- 
tients with a lower ejection fraction ati: more likely to be 
taking larger doses of diuretic agents and angiotensin- 
mnvertine enzvme inhibitors. we adiusned fur the effect of 
cottcomit&d d&tic agent or angibtensin-convening en- 
zyme inhibitor therapy. or both. Even after adJustinS for the 
differences in drug treatment and functional class. ejection 
fraction was significantly related to log plasma norepineph- 
tine (p < O.ooOl), log plasma renin activity (p < O.OKJIJ and 
Neurohormonekvels. bnctional class and bmitt wslk test. 
Figure 2 show the relation between functional class and the 
neurohormones. As with ejection fnction. as the functional 
status deteriorated in patients from functional class I to IV. 
there was an early increase in plasma attial nattiuretic 
peptide (p = o.MHJ3) and plasma renin activity (p = 0.0003) 
levels (class 1 vs. IIIAV). In contrast. plasma arginine 
vasopressin levels did not change significantly with a dete- 
rioration in functional class. Plasma norepinephrine levels 
differed significantly only between those in functional class 
IV versus classes I to III (p < 0.002). However, it should be 
noted that only a small number of patients were in functional 
class IV (I4 natien!s). Patients with a low eiection fraction 
and those’in a higher Rtnctional class were likely to be taking 
larger doses of diuretic agents or augiotensin-converting 
enzyme inhibitors, or both. When we adjusted for the effect 
of diuretic agent or nngiotensin-convertmg enzyme inhibitor 
therapy. or both, as weli as e,iectian fruction. the relation 
between functional class and ne~rohormone levels was less 
striking and was observed only with atrial natriuretic ueotide 
and pl&na renin activity in-patients in fnnctianalclasr I 
versus Ill/IV (atrial nattiuretic peptide. p < O.ooOl; plasma 
renin activity. p = 0.04) (Table 2). Because of the possible 
association between functional class and submaximal exer- 
case capacity. we also examined the correlation between the 
distance covered during the 6.min walk test and plasma 
neurohormone levels. Althongh the levels of all four ueuro- 
hormone< correlated statistical!:~ to the distance walked. 
these correlations were very weak <Table 3). 
Neumhormone levels and clinical variables. The relation 
between the four neurohormones and clinical variables is 
shown (Table 41. After adjusting for chnic and ehnlogy, the 
clinical variables associated with log plasma norepinephrine 
were age, elevated jugular venous pressure and third heart 
sound (S,) gallop. Significantly htgher plasma norepineph- 
rine irvels were present in older subjects (p = 0.062) and in 
Ftt 1. Relation between left Yen- 
tricular ejection fraction and Ihe four 
ncumhowoncs. Left ventricular ejec- 
tion fraction was grouped according to 
patients with ejection fraction 256% 
(9lpatients)55%to4W patients). 
45% to 3b% (138 patients), 35% to 26% 
(ll8 fmtic.lus), 25% to 16% (166 pa- 
tie,ItS) and <Iti (28 patients). Note 
the increase in p!asma norepinephrinc 
@@NE). plasma renin activity (PRA) 
and atrial natriuntic peptide (AXP) 
with increasing kti ventricular dys- 
function. In coaraot, argioine Yaw 
or&n IAVPI does not chance. Me- 
those with elevated jugular venous pressure (p = 0.02) and when clinic, etiology, ejection fraction, functional class and 
third heart sound (S,) gallop (p = O.OKJ3). Atrial natriuretic potential differences in drug therapy were adjusted between 
peptide levels were also significantly higher in older patients the two groups. The increase in plasma renin activity level 
(p = 0.0003). Patients with third heart sound (S1) gallop had was also significantly related to clcvated jugular veooos 
sigoitlcantly higher atrial natriuretic peptide levels @ = pressure @ = O.ooOl) end third heal wood (S,) gallop (p = 
O.wOI). as did those with pulmonary congestion on chest O.wOl). It is possible that in the more symptomatic patients, 
X-ray film (p = OHOI) and elevated jugular venous pressure larger doses of diuretic agents or angiotcnsinanverting 
@ = O.wOI). Age, race, elevated jugular venous preswre enzyme inhibitors may a&et plasma renin activity levds. 
and third heart sound (S,) gallop were associated with We therefore reexamined the relation between these clinical 
plasma renin activity. In contrast *’ plasma norepittephrine variables and plasma rain activiry, after adjusting for the 
and atrial natriuretic peptide, t~sma renin activity was effect of drug therapy. Even with this adjustment a signbi- 
signifiatly lower in older patients @ = 0.03). There was a cant relation was found bctwew increased plasma renin 
small but statistically significently higher plasma renin acliv- activity levels and third heal sound (S,) gallop @ = O.@NZ) 
ity in white patients than in black pat&& @ = 0.04), even and elevated jugular venous pressure @ = 0.003). In conlrast 
Table 2. Relation Betwden Neumhormones, Ejection Fmcdon and New York Heart Association Funcdond Class Wifh nnd Widwl 
Adjustment for Significant Covmiabkr” 
Neumhormone 
LosPNE 
!.mPRA 
IACC Vo!. 23. No. 6 BENEDICT ET AL. 1415 
May 19% 1410.20 NF”R”H”RM”NES AND “ENTRICULAR DYSF”NcTlON 
Table 3. Correlation of Fksrna Neurohormoner With Left 
Ventricular nimensions and h-min Walk Test 
~xurohunnone levels and left ventricular ejection fraction 
and functional class, we determined whelk the observed 
Rho 
p value 
LV diastolic volume (cm) 
Rho 
p value 
LA dimcnsien {cm) 
Rho 
p v3lue 
CTnlio 
Rho 
F-NE 
0.13 
o.ms 
0.06 
NS 
0.@4 
NS 
0.03 
PR4 
0.22 
CO.OlMl 
0.19 
CO.(wo1 
0 OS 
NS 
-0.02 
AYP 
0.10 
o.om 
0.10 
0.007 
0.08 
NS 
0. IO 
ANP re&tion between neurobonnone levels and various clinical 
- 
0.30 
<o.WOr 
Futures was dependent on the degree of underlying left 
ventricular dysfunction or functional class. For plasma nor- 
epinc_rhrine and plasma renin activity, when the influence of 
ejection fraction and functional class was controlled. onlv 
0.x 
<V.ooaI 
0 34 
co.cW 
0.30 
;ite p~.t~tice of third heart sound (S,) gallop rer&nkd 
s;;nificantly related to plasma norepinephrine (P = 0.03) or 
pksma renin activity @ = 0.04) t&Is. hr atrial natriuretic 
peptide and arginine vasopressin, when the inRuence of 
qjection fraction and functional class was controlled. only 
oulmonarv edema on cheat X-rav lilm remained related to 
p value NS NS 0.02 <O.oWI 
bmin walk distance Cm) 
kaJ natriuretic peptide (p = 0.009) and arginine vasopres- 
Rho -0.10 -0.11 -0.12 -O.IP 
w. !p = 0.86) levels. 
p value 0.0X 0.0X O.W? 10.ooo1 Relation belwen drug therapy and phx~mn neurohomooe 
ANP = ati natriurctic p&de; AVP = aqmocumopresrin~CTratm = 
heels. Treatment with diuretic agents and angiotensin- 
cmdbthomic ratio; LA = left ahim; LV = left veniricls; PNE = plasma converting enzyme inhibitors is known to increase plasma 
nwspinephrine; PRA = plasma reti activity: Rho = Speurmsn ra&order n:nin activity. Therefore, we examined the effect of diuretic 
comlation ct&Citnt. a.i,L’nts with and without angiotensin-converting enzyme in- 
hibitor therapy on plasma neurohormone levels (Table 51. 
Significantly elevated levels of plasma norepinephrine (p = 
to the other three neurohormones, arginine vasopressin was @.114), plasma renin activity (p < O.tJUOl), atrial natriuretic 
not significantly associated with age or clinical findings of prptrde (p < O.CKtW and argininc vasopressin (p = O.@M3) 
congestive hem? failure, except for elevated jugular venous wre found in patients with than without diuretic agent 
pressure (p = 0.03) and pulmonary edema on chest X-ray therapy. Addition of angiotensin-converting enzyme inhibi- 
film (p = 0.003). tars (enalapril. captopril or lisinopril) significantly increased 
Elevated jugular venous pressure or third heart sound pirsma renin activity levels only, regardless of whether the 
(S,) gallop are more IikeIy to occur in patients with lower patient had diuretic agent therapy or not (p < O.GiIOl). 
ejection fixction or in those in a higher functional class. It is possible that the more symptomatic patients may 
Becaux there was a signiticaot relation between plasma have received more diuretic agent or angiotensin-converting 
Fb 2. Relation between New York Heart 
ArMciation (NYHA) functional class and the 
four twohormvnes. Functional classes were 
groupa as fullowr: CIPSS I = 306 patients; class 
11 = 397 patients; class III = 127 patients; class 
IV = I4 patients. Note that argiaine vasopre+ 
sin (AVP) does not increase with a deletior&n 
in functional class. Plasma norepinephrine 
(PNE) increaser significantly only when the 
patient’s condition deteriorates to class IV. 
Both plasm nnin activity (PRA) and atrial 
nmiurclic pcptide (ANP) show an early in- 
crease as functional class deteriorates and are 
not signi%cantly different in class IV patients. 
Median values and intequarlile ranges (25% la 
75%) are shown. 
WSOP?ESSlh ATRIAL NATRluRETlC PEPTIDE 
6r 
200 - 
I53 
241 
303 
93 
16 
179 
633 
96 
684 
I5 
+t9 
192 
It0 
69 
32 
61 
II 
169 
695 
I95 
J42 
3+1 
M 
392 
+I5 
:2, 
685 
375 1286-559, 
397 UOi-f57, 
+2, t32Lw 
+82 1167-612, 
525 (IM-736, 
426 1336-605) 
+16(308-58383) 
411 Oil-Ull 
ru (317S6, 
395 uD3-+w 
+t5 (310-593, 
+28 (322-592, 
a+ l314-5+8, 
+52 (30s626, 
390!256-538, 
+65 w-651, 
I15 (312-583, 
186 (363-626, 
+a 009-586, 
433 (329-617) 
42x3 1310-591, 
1% 
242 
x6 
93 
I6 
t*3 
637 
97 
691 
I5 
a5 
191 
IM 
68 
31 
61 
759 
I09 
703 
I97 
552 
348 
345 
391 
+22 
I25 
690 
I.74 (0.3-6.7, 
I.Y (O.IJ.B, 
1.2 :0.+-+.9j 
1.2 to.+-3.8, 
0.8 ,0.*1.1) 
I.3 to.+-1.0, 
I.3 (O.,-l.7, 
I25 2.2 (1.7-3.0) 12, 57,35-128, 
223 2.2 (1.7-2.8, 222 6a 14bl22, 
m *.3 w-3.0, 279 79 (4~IO, 
95 2.1 ,1.7-2.9, 95 e4 t5:-116, 
I6 2.2 11.7-3.0 16 112 (47-129, 
167 
57, 
2.1 w-2.n 
2.2 !1.7-3.0, 
167 
570 
67 w-,30, 
74 (+%!32, 
0.6 (0.8-2.7, 
1.5 (OS+.9, 
0.5 ,O.o)-2.3, 
1.2 (0.4-3.8) 
l.S (0.5-5.6, 
0.9 ,O.?--4.3, 
2.0 tO.+-6.8, 
1.3 to.+-3.+, 
l.9 (0.~1l.B 
I.3 to.+-3.6, 
62 2.6 (2.0-3.8) 62 7R (19-167, 
628 2.2 u.7-2.8, 62n 71 <+2--129) 
12 1.1 U.M.2) I! 6% ,+*-w.2, 
3% 2.1 (1.7-2.7) 396 69 (11-122, 
162 2.2 t1.7-3.0) ‘62 75 ,++-I%) 
93 2.3 ,1.8-3.0, 69 % w1+5l 
% 2.+(2.0-3.8, 56 76,3+-139) 
32 2.8 l2.L3.0 32 76 w-132, 
52 
671 
2.6,2.6-3.+, 
I!.2 tt.7-2.8, 
5, 
677 
3.5 (1.1-9.4) 93 2.3 tl.9-3.0) 62 117 (fO-!r4) 
I.2 IOA-3.6, 637 2.2 (i.7-2.B) 637 69 :+1-w 
I.* (0.S6.3, 
I.3 IO 4.40, 
I.5 (0.6-4.0, 
I.3 (0.4-4.7) 
I67 2.5 (2.0~3.5, I67 IO, w-w 
.%9 2.1 w-1.8, Jcs 67 NO-122, 
311 2.2 (!.7-2.6, 311 61 tM-IW, 
315 2.3 It.&3.1) II+ R t%l67, 
2.2 (0.6-6.9) 357 2 3 II&3.2) 356 
I.0 w-2.4, 376 2.1 0.7~2.n 376 
0.6 (0.*-w 
:i: 
1.0 ,I .7-2.6, 117 
2.7 (1.7-2.9) 615 1.6 tO.5-5.2) 
enzyme inhibitor therapy, or both, and the observed relation 
between drugs and neurobonnones may have been related to 
the lower ejection fraction or higher functionai cbw in these 
patients. When the effects of ejection fraction and functional 
class as well us clinic and etioloav were adiusted, diuretic _. 
agent or a@tensin-converting enzyme inhibitor therapy or 
both. sienitkantlv altered olasma renin octivitv ID < O.ooOl~ 
and &% natrketic pepiide (p = 0.02) levels only. Tb; 
median plasma renin activity level in patients without di- 
uretic agents or angiotensin-converting enzyme inhibitors 
was 0.5 &ml oer h (ranae 0.2 to 1.2) (217 uatients). This 
increased& I.% n&l per h (range 0.4 to 2.7j (193 p&us) 
with the addition of a diuretic agent and to 2.9 nglml per h 
(range 0.S to 11.4) (63 patients) when nn angiotcnsiw 
converting enzyme inhibitor was added. ‘% hi&a levels, 
3.8 ng/ml per h (range l.lS to 10.3). were observed iu 
patients receiving both diuretic agent and angiotensin- 
convenina enzyme inhibitor (232 uatients). A similar in- 
crease inmedkn atrial natriuktic .&ptiC levels .vas atso 
noted with diuretic agent or angiotensin-converting enzyine 
inhibitor therapy, or both. The lowest levels (56.4 p&t. 
range 37.0 to 94.0) were %xn in ptients receiving neither 
angiotensin-converting enzyme inbibi!ore nur diuretic 
agents. With either angiotensinanverting enzyme inhibitor 
or diuretic ager~t only, the level of atrial natrieretic peptide 
increased to 70.6 p#ml (range 39.2 to 121.3) wd 85.6 p&d 
(taoge 48.1 to 152.1). respectively. As with plasma rain 
activiry. the highest levels of atrial na:riuretic peptide were 
observed in patients receiving both diuretic agents and 
aogiotensinconverting enzyme inhibitors (87.6 pgiml. range 
51.7 to 145.3). Of the other drugs. treatment with digitalis 
and beta-bloeken also had B s&ifxaot effect on p~won 
retin activity and atrial natrhuetic peptide levels. atler 
adjusting for ejection fraction, functional class, clinic and 
etiology. Digitalis use was significantly associated with in- 
creased plasma rain activity (p < O.WI) sod atria! natri- 
untic peptide @ = 0.04) levels. Beta-blocker use was 
associated with decreased plasma rain activity (p < O.WJ31 
and inc.w?.ed atrial natriuretic peptide ip = 0.04) levels. 
Diiossion 
Neurohumoml activation is on important maoifesiztion of 
heart futlure. Revious studies have focused predominantly 
oo patienrs with severe congestive heart failure. To dotr. :his 
is the largest study to examine neurohumonl activity in 
patients with a broad ruoge of letI ventricular dysfuncticn 
and congestive heart failure. Furthermore. patients in this 
study we.z not recruited on the basis of eligibibty for a 
therapeutic trial sod are thus likeiy to be mare representative 
of the popukuion of patients with left ventriwlar dgsfunc- 
tion. These results show :hat when compared with age- ad 
gender-matched contmi sul$ects, all four neurohormones 
are elevated in patients with leR ven:p.cuIur dysfunction. 
The wid: range c’ neurohormonal levels sqgests highly 
wizb!e oeurohumoffil activdy in ihw patients. When 
rstiects develop congestive hean failure secondary to im- 
p&mec: of left ventricular function. there is an iincriase in 
oeoroendocrme a&it), ever! at :he expense of increased 
blo& rolux and further reduction of myocardial function 
(19. Therefore. it is not wronsinz ;ba: we found a sianificant 
I- ~~~ . - 
relation between elevated levels of plasma Rorepinephri!x 
plaina renin xtivity avd atnal natriuwhc peptide and third 
heart sound (S,) gallop wd elevated jugular ,eoous pres- 
scre. 
l%smp oorqinephrbte, Ali four newohti.rmones were 
setistictij sigoificaotly out weakly correlated with left 
veotricuiar ejection fraction, with atrial natriuretic peptide 
showing the best correlation. This relation was demonstnble 
even after excluding the e&I of dmg therapy on various 
neurohomtones. The absolute p!asma norepinephrine level 
in patwnts with congestive hear? failure is influenced by 
alterations in neumnal uptake and cleannce and merabulism 
of norepinephrhx released fmm the sympathetic nerve end- 
ings. However. measurement of efferent sympathetic nerve 
tnflic by intnneuronal recording in the perone.d nerve in 
patients with heart failure demonstxates evidence of in- 
creased central sympathetic outtlow (20). If the stimulus for 
activodon of the sympathetic oervous system is pax pump 
function. then it is not unreasonable to expect a correlation 
between left ventticulw ejection fraction and plasma norepi- 
naphrine levels. Previous clinkal studies in patien*e with 
moderate to severe congestive heart failure have shown a 
weak correlation between the hemodyramic severity of 
congestire heart failure and plasma norepinephrine !evels 
(8.21). This study also demonstrated a weak correlation 
betwew plasma norepinephrine and left ventricular ejection 
hartion in ao a.paoded cohort of patients with a broader 
spectrum of left ventricular dysfunction. 
Pbtsma ret&t activity. The neurohormones to show the 
strongest correlation with ejection fraction were plasma 
wnin activity and otrial nattiuretic peptide, which increased 
as eiection fraction declined. This relation was consistent in 
patients with and without diuretic agents or angioteitsin- 
converting enzyme inhibitors, or both. Although sevenl 
studies have reported stimulation of the renin-angiotensin 
system in congestive heart failure. there is no agreement as 
to its frequency or magnitude m patients with varying 
degrees of heart failure. Dzau et al. (22) reported that the 
system is markedly activated during acute decumpensation 
but is near normal when patients have recovered from the 
a;ute episode. Therefore. the clinical status of the patient in 
congestive heart failure (compensated or decampensated) 
will affect the measured plasma ratin activity levels. Fur- 
ther. diuretic agent use and sodium restriction tiect the 
rain-angiotensin system and increase plasma renin activity 
(23.24). However, Anand et al. (25) showed that five of eight 
patients with advanced, untrented chronic coogesthe heart 
failure, with sirlt and water retention. had elevated plasma 
r&n activily levels. Similar findings have been reported by 
Brown et al. (26) in untreated patients with congestive heart 
failure. These dab suggest that depending on the cohxt of 
w:ienrs investirated and the clinical severity of congestive 
hean failure ir&lved and treatments used, plasma xnin 
activity levels can vary significantly In this study. we 
investigated patients with varying severity of congestive 
hxI failure who were taking a wide variety of drugs. Even 
when we controlled for the effect of diuretic agent or 
angiotensiuconverting enzyme inhibitor therapy, or both, 
there was a significant relalion between ejeciion frac!ion and 
plasma rcnin aclivity. This suggests that severity cf left 
ventricular dysfunctian. either directly (inadequate renal 
pctiusion) or indirectly (renal sympathetir. stimulation and 
renin releastl. or both, may modulate the plasma renin 
acrivity measured in palienls with congestive heart failure. 
Atrlnl natriurelk pptide. Atrial natriuretic peptide is 
synthesized in the myocardium and released mainly in 
rcsponsr. to increased atrial stretching (27). Plzsma atrial 
natriurclic peptide levels increase with increased atrial pros- 
sure and alrial stretch in patients wilh worsenb~g heart 
fail.rre (28.29). Ham et al. (IO) found that atrial ttattiureiic 
peptide levels in plasma correlate inversely with the level of 
tjection fraction and directly with the severity of heart 
failure. Similarly, Rouleau et al. (31) found an inverse 
cnrrelatian between atrial natriuretic peptide and cardiac 
index. In this study atrinl natriuretic peptide was inversely 
carrelated to ejection fraction. More important, iI was the 
hormone that correlated most strongly with left atrial and left 
ventricular systolic and diastolic dimensions as well us with 
cardioIhorwic ratio. However. these correlations were mod- 
PSI, which could hnve been due to the fact that the atrial 
dimensiuna measured by two-dimensional echocardiography 
may not correla~c strongly with left atrial pressure 81 a result 
of stretching and alterations in alrial compliance in patieuts 
with chronic hearI failure (32). the cardiolhoracic ra!io cnuld 
also be altered by Ihc presence uf concomitant lung disearc. 
Because palients with increased catidiac size are nwsI I!xelv 
to huve elevated jugular venuus pressure. pulmonary con- 
gestion on chest X-ray film and clinical evidence ofconges- 
live heart failure, it is nut surprising that the elevated levels 
of alrial natriuretic peptide wure ulso significantly related to 
these clinical findings. 
Arglm vasuprwin. Of the four neumhormones exan- 
ined. plasma arginine vasopressin levels showed the smallest 
increase in p:tlients with congestive hcan failure compared 
with nomxd subjects and showed the weakest association 
with a diBerence in ejection fracraction or funciional class. This 
may be due IO the fact that in congestive heart failure Ihere 
is an augmentation of the release of arginine vasapressin, 
which may not increase further as the clinical condition 
dateriurates. Although a previous study demonsirdted an 
increase in arginine vasopressin levels in direct proportion tu 
hemudynamic and clinical severity of heart failure (S), the 
Present study failed to show a strong relation between 
argininc varapressin and ejection fracti;m or functional 
cluss. In congestive heart failure the Precise mechanism for 
Ihc release af arginine vasopressin is unc!ear but is believed 
to be due to nonosmotic causes (33.34). Plasma wginiae 
wsopr.%in and Plasma rain activity (35) levels are fre- 
quen~ly increased in Parallel because if compromised end- 
organ periiusion. Furthernmre. barureceptor stimulation is a 
commun stimulus for release of both arginine vasoprewiu 
and plasma renin aclivity, and increases in ang;atensin II 
may directly stimulate the hypophyseal production of arr- 
sine vasopressin (36). Although we obscrded Pr.vessive 
increases in plasma renin activity with increasing left ven- 
tricular dysfunction, there was no increase in arginine vasu- 
pressin levels. This suggests that release of arginine vasopres- 
sin is probably nut a Plimary mechanism for the maintenance 
of peripheral resistance in most patients with congestive 
hean failure, and the nonosmotic mechanisms of argbtine 
vasopressin rekasc may induce only a limited increase in 
plasma &nine varuprersin levels. 
RUeci of dru# therapy. In previous studies in patients 
with severe congestive heart failure. hemadynamir: indexes 
of cardiac function or Id ventricular ejectiun fraction have 
been shown to bear little relation IO the tneasures of fuac. 
lional status or exercise capacily (37.38). Tberefox WC also 
examined the relation bctwe:n the mumbormm~s and 
functional class and the Cmin walk test. llwe was no 
association belwecn arginiue vasoprcssin and functional 
class. wbiih is consistent with the possibility that arginiue 
vasopressin may MH be a Primary neurobunnum aclivated 
in heart failure. Plasma norepincphrine was sipilicantly 
higher only in patients in functional class IV. This is similar 
to findings that patients wiIb severe symptomstic hean 
failure have the highest plasma norepincphrine levels 
(39,40). However, it should be noted that there wcrc only 14 
patients in onr study with functional class IV symptoms. 
Therefore. this finding musl be interpreled with caution 
because Ihe small number of patients in this group may have 
produced Ihis relation. In conIrast plasma renin activity and 
atrial nalrlurelic peplide showed an increase in patients with 
functionul class II symptoms. TnL walk1 increase in both 
hornmnes as the functional capacity decreases is nut surpris- 
ing because many of the physiologic effects of at&l nstri- 
urelic peptide oppose the effccfs of the rettin-angiotensin 
system. Thus. rhe secretion of a!rial pcptides may increase 
to counteract many of Ihc detrimental circulatory and renal 
effects of angiotcnsin II. Wesk but statistically significant 
correlations were found between exercise capacity (&min 
walk testl and ull four ueurohormones. This indicates that 
ulthougb patients with neurohumoral activation also have 
impairment of exercise capacity. it is likely that other 
mechanisms influence the patient’s ability tu exercise. 
Fuuctklnal cap&y and ne~Imbormoncp. Wha the ef- 
fects of diuretic agents nr angiatensinamverting enzyme 
inhibitors, or both, were adjusted using a multivariate R- 
gression model, patients with lower ejection fraction were 
found to have signilicanIly higher plasma norepinephrine, 
atrial nalriuretic pepiide and pbsma renin a&it‘/ I?Y& 
*whereas those in a higher functmnal class had s,&ican,ly 
higher levels of a,rial natriure,~ pep,ide ad plasma renin 
activity. Similarly. other studier. have ahown high plzsmd 
norepinephrine (25) or plasma rain octiwty levels 1251 in 
patients with untreated hean ia!lurc. When diuretic agent, 
and ac&ensinconvcr,ing enzyme tnhibiron are added fur 
the maoagement of con:es,ive heart failure. patients have a 
significant increase in plasma renin activity level. 1241. The 
increase in plasmr? rain activity with aogiocnsin-convc~ting 
enzyme inhibitor therapy is usu;llly secondary to the de- 
crease in angiotensin II levels :n ihe c~rcul~~inn. rrhrcb leada 
,o a reflex increase in plasma renin activity lwels becane oi 
the absence of neEil1ii.e fcedbxk. Therefore. 1115 rcdsonable 
to assume that -&ems with low ejection fmclao had 
increased neurohormonal levels tha, increased funher wrh 
the addition of concomitant diuretic age”, or anpm,en& 
converting enzyme inhibitor therapy. or both. 
Conclusions. This study broadcns our understanding of 
the neurohumoral activation that was ablainrd from ihe lirs, 
SOLVD neurohormonal study, which showcd ,hn, nrurocn- 
do&E activation OEcUrs in aSy~mplOnl.liiC pi&cnb wilh 
depressed left ventricular ejection froctiw and IS mcrcascd 
further with development oi symptoms ond addiuot! of drug 
therapy (411. The results from this study bhggcs, lhat in 
patients with congestive heart Ulure, the incrensc in plasma 
newohormonal levels may be linked ton depression in lef, 
vemricular ejection fraction that is modslakd by a compkx 
interplay between symptoms. ap of the patient and the 
medications used for treatment. 
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